Journal article

Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial

H Brodaty, D Ames, J Snowdon, M Woodward, J Kirwan, R Clarnette, E Lee, A Greenspan

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY | JOHN WILEY & SONS LTD | Published : 2005

Abstract

OBJECTIVE: To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of Alzheimer's disease (AD) and mixed dementia (MD) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidone for aggression. METHOD: This post-hoc analysis included only patients diagnosed with AD or MD with psychosis, defined by a score of >or= 2 on any item of the Behavioral Pathology of Alzheimer's Disease (BEHAVE-AD) psychosis subscale at both screening and baseline. Co-primary efficacy endpoints were changes in scores on BEHAVE-AD psychosis subscale and Clinical Global Impression of Change (CGI-C). RE..

View full abstract

University of Melbourne Researchers